Skip to main content

Cencora, Inc. company profile

  • COR · NYSE
  • Distribution
  • Health Care Distributors
  • S&P 500
$356.94−0.58%Close 16 Nov 2026 · Market value $67.23B

About Cencora, Inc.

Cencora is a global pharmaceutical sourcing and distribution services company serving healthcare providers and pharmaceutical and biotech manufacturers in the United States and select global markets, as well as in human and animal health. It distributes brand-name, specialty brand-name, and generic pharmaceuticals, over-the-counter healthcare products, and home healthcare supplies and equipment to customers including acute care hospitals, health systems, retail and mail order pharmacies, medical and dialysis clinics, physician practices, and veterinarians. It also provides services such as data analytics, reimbursement and pharmaceutical consulting, specialty logistics, inventory management, pharmacy automation, and packaging solutions. Its operations are organized into U.S. Healthcare Solutions and International Healthcare Solutions, with the international segment operating primarily in Europe and Canada.

A summary of the business section of the company's latest annual report, filed 25 Nov 2025.

Company facts

TickerCOR · NYSE
SectorDistribution
IndustryHealth Care Distributors
IndexS&P 500
Fiscal year ends30 September
Reporting currencyUSD
CIK1140859
Latest annual report10-K, filed 25 Nov 2025

Officers and directors

NameRoleShares ownedLatest Form 4
Steven H. CollisFormer Executive Chairman and Director381K · < 1%Option exercise, 16 Sep 2025
James F. ClearyExecutive Vice President and Chief Financial Officer146K · < 1%Option exercise, 11 Mar 2026
Robert P. MauchPresident, Chief Executive Officer and Director115K · < 1%Option exercise, 12 Nov 2026
Elizabeth S. CampbellExecutive Vice President and Chief Legal Officer27.2K · < 1%Option exercise, 12 Nov 2026
D. Mark DurcanDirector21.9K · < 1%Open-market purchase, 18 Jun 2026
Silvana BattagliaExecutive Vice President and Chief Human Resources Officer20.5K · < 1%Grant or award, 30 Jun 2026
Lon R. GreenbergDirector17.1K · < 1%Open-market sale, 16 Sep 2026
Dennis M. NallyDirector12.7K · < 1%Grant or award, 30 Oct 2026
Redonda G. Miller, M.D.Director1.6K · < 1%Grant or award, 5 Mar 2026
Lauren M. TylerDirector426 · < 1%Grant or award, 30 Oct 2026
Frank K. ClyburnDirector378 · < 1%Grant or award, 5 Mar 2026
Lorence H. Kim, M.D.Director168 · < 1%Grant or award, 5 Mar 2026
Verma PawanEVP, Chief Data &amp; Info Officer—Option exercise, 12 Nov 2026
Krikorian LazarusSVP &amp; Chief Accounting Officer—Option exercise, 12 Nov 2026
Ellen G. CooperDirector—Grant or award, 30 Oct 2026
SANCHEZ ROBERT EDirector—Grant or award, 1 Oct 2026
Werner BaumannDirector—Grant or award, 5 Mar 2026
Lori J. RyerkerkDirector—Grant or award, 5 Mar 2026

Holdings as the latest proxy statement states them, all forms counted; the latest Form 4 line each filed. People appointed since the proxy are listed from their Form 4 filings.

COR in the terminal

The business section of every annual report, officers' holdings and trades, and the company's filings as they arrive.